Los Angeles Capital Management LLC Lowers Stake in Kodiak Sciences Inc. (NASDAQ:KOD)

Los Angeles Capital Management LLC cut its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 11.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 105,370 shares of the company’s stock after selling 13,759 shares during the period. Los Angeles Capital Management LLC owned approximately 0.20% of Kodiak Sciences worth $275,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of KOD. American Century Companies Inc. increased its holdings in Kodiak Sciences by 18.5% in the 2nd quarter. American Century Companies Inc. now owns 54,323 shares of the company’s stock worth $128,000 after acquiring an additional 8,470 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Kodiak Sciences by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,654,448 shares of the company’s stock worth $8,702,000 after purchasing an additional 10,978 shares during the last quarter. Nan Fung Group Holdings Ltd lifted its stake in Kodiak Sciences by 62.7% in the 1st quarter. Nan Fung Group Holdings Ltd now owns 31,922 shares of the company’s stock valued at $168,000 after buying an additional 12,300 shares in the last quarter. SG Americas Securities LLC purchased a new position in Kodiak Sciences in the 3rd quarter valued at about $33,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Kodiak Sciences in the 1st quarter worth about $68,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on KOD shares. Barclays raised their target price on Kodiak Sciences from $3.00 to $4.00 and gave the company an “underweight” rating in a research report on Friday. HC Wainwright restated a “neutral” rating and issued a $3.00 price objective on shares of Kodiak Sciences in a report on Friday.

Kodiak Sciences Trading Up 2.4 %

NASDAQ:KOD opened at $5.66 on Tuesday. The stock has a fifty day moving average price of $3.42 and a 200 day moving average price of $3.06. Kodiak Sciences Inc. has a 12-month low of $2.18 and a 12-month high of $7.77. The firm has a market cap of $297.83 million, a PE ratio of -1.55 and a beta of 2.26.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.